Successful desensitization in a patient with recurrent anaplastic oligodendroglioma presenting with procarbazine-mediated anaphylaxis.

Autor:	Kayikçi H; Faculty of Medicine, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey., Can Bostan Ö; Faculty of Medicine, Division of Allergy and Clinical Immunology, Adıyaman University Education and Training Hospital, Adıyaman, Turkey., Tuncay G; Faculty of Medicine, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey., Cihanbeylerden M; Faculty of Medicine, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey., Tüccar Ç; Faculty of Medicine, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey., Damadoglu E; Faculty of Medicine, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey., Karakaya G; Faculty of Medicine, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey., Kalyoncu AF; Faculty of Medicine, Division of Allergy and Clinical Immunology, Hacettepe University Hospital, Ankara, Turkey.
Jazyk:	angličtina
Zdroj:	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2024 Jul; Vol. 30 (5), pp. 937-940. Date of Electronic Publication: 2024 Jan 22.
DOI:	10.1177/10781552241226861
Abstrakt:	Introduction: Procarbazine is an oral chemotherapeutic agent used in the treatment of brain malignancies and is associated with hypersensitivity reactions. In case of grade 4 reactions, rechallenge should be avoided, and the agent should be replaced, unless the treatment is curative, in which case the application of a desensitization protocol should be considered. We present a successful case of desensitization in procarbazine anaphylaxis. Case Report: A 53-year-old male patient was diagnosed with recurrent anaplastic oligodendroglioblastoma. The patient received three cycles of procarbazine, lomustine, and vincristine chemotherapy for malignancy recurrence. In the fourth cycle, on the 12th day of procarbazine treatment, the patient developed anaphylaxis. Procarbazine was given together with premedication as part of the 12-step desensitization process, and the fourth cycle was successfully completed. Management and Outcome: Procarbazine hypersensitivity reactions are observed less frequently than reactions to other chemotherapeutics. We presented a case of procarbazine-associated severe anaphylaxis that was able to continue procarbazine chemotherapy with successful desensitization. This case is important in terms of confirming the procarbazine desensitization protocol. Discussion: In literature there is only one protocol developed was successfully applied in one patient with procarbazine anaphylaxis. In the current case, we took this protocol into consideration in the management of our patient. Following the use of this protocol, the patient was able to continue procarbazine chemotherapy successfully. Procarbazine anaphylaxis is rare, and more cases are needed to be reported to confirm the desensitization protocol and when to continue procarbazine treatment. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu